Lpath Inc. (LPTN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.90-0.15 (-4.92%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close3.05
Bid1.80 x 500
Ask3.20 x 700
Day's Range2.86 - 3.02
52wk Range1.68 - 5.88
1y Target EstN/A
Market Cap6.89M
P/E Ratio (ttm)-0.73
Avg Vol (3m)315,980
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire2 months ago

    Apollo Endosurgery and Lpath Sign Merger Agreement

    AUSTIN, Texas and SAN DIEGO, Sept. 8, 2016 /PRNewswire/ -- Lpath, Inc. (LPTN) and Apollo Endosurgery, Inc. today announced that they have entered into a definitive merger agreement under which the security holders of Apollo would become the majority owners of Lpath. Under terms of the agreement, Lpath will issue new shares of its common stock or rights to acquire its common stock to Apollo security holders.

  • Capital Cube2 months ago

    Lpath, Inc. :LPTN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016

    Categories: Yahoo Finance Click here to see latest analysis Lpath, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Lpath, Inc. – PDL BioPharma, Inc., Ohr Pharmaceutical, Inc., Gilead Sciences, Inc., Pfizer Inc., Acorda Therapeutics, Inc. and Merck & Co., Inc. (PDLI-US, OHRP-US, GILD-US, PFE-US, ACOR-US ... Read more (Read more...)

  • Zacks4 months ago

    Why is Lpath (LPTN) Stock Skyrocketing Today?

    On Monday, shares of lipid-based therapeutics company Lpath Inc. (LPTN) are skyrocketing, up over 58% in afternoon trading after the company announced that it has been awarded a $1.45 million two-year grant by the Defense Medical Research and Development Program (DMRDP).